IMNM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunome (IMNM) is a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has a strong event-driven setup after filing an NDA for varegacestat following positive Phase 3 results, which is a major long-term catalyst. Analyst sentiment is broadly positive, hedge funds are accumulating, and the balance sheet strength supports runway into 2028. Despite weak recent financials and no AI Stock Picker or SwingMax signal today, the overall setup favors buying now rather than waiting, especially for a long-term position.
IMNM is trading pre-market at 22.94, slightly below pivot resistance at 23.685 and just above first support at 22.783. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports the broader trend. However, the MACD histogram is negative and expanding, showing short-term momentum weakness, while RSI_6 at 42.695 is neutral. Overall, the technical picture is mixed-to-positive: the longer-term trend remains constructive, but near-term momentum is not strong. The stock trend model suggests a 60% chance of a 1.2% move higher next day, but only modest follow-through over the week.
["NDA submitted for varegacestat after positive Phase 3 RINGSIDE results", "Confirmed objective response rate of 56% and significant progression-free survival improvement", "Analyst community remains constructive with multiple Buy/Overweight ratings", "Price targets remain well above the current price range, indicating upside potential", "Hedge funds are buying aggressively, with buying up 577.15% over the last quarter", "Company balance sheet strengthened, extending cash runway into 2028", "Multiple ADC catalysts ahead according to analysts"]
["MACD histogram is negative and worsening, signaling short-term momentum weakness", "Latest quarter revenue dropped to zero", "Net loss remains substantial at $69.9M", "EPS declined further year over year", "No AI Stock Picker signal today", "No SwingMax signal recently", "Insider trading activity is neutral", "No congress trading data available"]
In Q4 2025, Immunome reported no revenue, which was down 100% year over year, while net income was a loss of $69.9M and EPS was -0.74. Gross margin was 100%, but that is not meaningful without product revenue. The key positive financial development is the strengthened balance sheet, which extends cash runway into 2028. For a biotech name, this makes the company financially better positioned to execute through upcoming catalysts, even though current operating results remain weak.
Recent analyst trend is positive overall, though price targets have been mixed. JPMorgan raised its target to $39 and keeps Overweight; Craig-Hallum raised to $36 and keeps Buy; H.C. Wainwright initiated Buy at $40; Stephens lowered to $30 while keeping Overweight; Lake Street lowered to $30 but kept Buy. The Wall Street pros view is constructive: they see commercialization transition, protected downside from the stronger balance sheet, and upside tied to desmoid differentiation and upcoming catalysts. The main con is that some analysts have trimmed targets after the Q4 update, reflecting near-term uncertainty around execution.
